Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Email Alerts Madrigal press releases are available below. Search them by keyword or browse by date. Year None20232022202120202019201820172016 November 27, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) November 21, 2023 Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer November 15, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) November 10, 2023 Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health November 10, 2023 Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer November 6, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results November 2, 2023 Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences October 12, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) September 28, 2023 Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering September 28, 2023 Madrigal Pharmaceuticals Announces Proposed Public Offering Pagination Current page 1 Page 2 Page 3 Next page
Madrigal press releases are available below. Search them by keyword or browse by date. Year None20232022202120202019201820172016 November 27, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) November 21, 2023 Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer November 15, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) November 10, 2023 Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health November 10, 2023 Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer November 6, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results November 2, 2023 Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences October 12, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) September 28, 2023 Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering September 28, 2023 Madrigal Pharmaceuticals Announces Proposed Public Offering Pagination Current page 1 Page 2 Page 3 Next page
November 27, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 15, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023 Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health
November 6, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
November 2, 2023 Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
October 12, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
